Aptose Biosciences (APTO) Received its Third Buy in a Row


After RBC Capital and H.C. Wainwright gave Aptose Biosciences (NASDAQ: APTO) a Buy rating last month, the company received another Buy, this time from Canaccord Genuity. Analyst John Newman maintained a Buy rating on Aptose Biosciences today and set a price target of $13.00. The company’s shares closed last Friday at $6.12.

According to TipRanks.com, Newman is a 5-star analyst with an average return of 26.8% and a 48.2% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Atara Biotherapeutics.

Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $10.43, implying a 64.3% upside from current levels. In a report issued on November 30, RBC Capital also maintained a Buy rating on the stock with a $9.00 price target.

See today’s analyst top recommended stocks >>

Based on Aptose Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $13.25 million. In comparison, last year the company had a GAAP net loss of $6.84 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts